Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presented today results from the Phase III SUNMO ...

Genentech, part of the Roche Group (OTCQX:RHHBY), said that a late-stage study testing Lunsumio, along with Polivy, showed ...

Adding polatuzumab vedotin (Polivy) to standard-of-care treatment significantly improved overall survival (OS) in patients ...

Polivy is a type of targeted therapy called an antibody-drug conjugate. This antibody-drug conjugate is made up of an antibody that is attached to an anti-cancer medicine. Polivy is used to treat ...

As with other drugs, Polivy (polatuzumab vedotin-piiq) can cause side effects, such as nausea, fatigue, and diarrhea. If side effects of Polivy become difficult to tolerate, talk with your doctor ...

Polivy (polatuzumab vedotin-piiq) is a prescription biologic drug that treats certain types of B-cell lymphoma. Polivy can cause side effects that range from mild to serious. Examples include ...

The regulatory decision announced Wednesday converts the status of the drug, Polivy, to full FDA approval. Polivy treats diffuse large B-cell lymphoma (DLBCL), a cancer that starts in white blood ...

Pivotal phase III SUNMO study demonstrated an 11.5 month median progression-free survival - three times longer than ...